Brief: Sprint Bioscience Q2 Operating Loss Widens To SEK 6.8 Mln
Aug 27 (Reuters) - Sprint Bioscience AB SPRINT.ST: Q2 NET SALES SEK 13.9 (16.7) MILLION Q2 OPERATING PROFIT SEK -6.8 (-5.6) MILLION Source text: ID:nMFN6YfFCb Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln